Peptide education
Adamax
Ac-MEHFPGPAG-NH2 · Semax analogue · ACTH analogue
Adamax is a Semax analog that vendors, not researchers, brought into circulation: the Semax sequence reportedly extended and fitted with an adamantane group, listed as Ac-MEHFPGPAG-NH2. It is sold as longer Semax, and that phrase is the whole story: no published study of any kind, human or animal, characterizes the molecule. What exists is a name, a reported sequence, scattered forum doses copied from Semax, and a Medsafe filing that noticed it only as an import problem.
Longer Semax is a marketing sentence, not a finding. No published study, human or animal, has characterized Adamax, and the dose numbers circulating for it are Semax numbers with a new label on them.
Overview
Quick answer
Adamax is a Semax-family analogue whose reputation mostly comes from Semax. Parent-Semax studies explain why the family attracts attention for focus, mood, and neurorecovery, but they do not answer the basic Adamax questions: how long it lasts, how it compares with Semax, what repeated use looks like, and what safety profile it has.
What is Adamax?
A Semax-family analog with a reported sequence of Ac-MEHFPGPAG-NH2: Semax extended and fitted with an adamantane group that is supposed to make it last longer. Supposed is the operative word. The molecule exists in vendor catalogs and a chemical summary, not in the research literature.
Why do people compare it to Semax?
Because there is nothing else to compare it to. Semax has Russian clinical literature and animal mechanism work; Adamax has none, so the entire case for it is Semax's reputation plus a chemistry argument about stability.
What do people use it for or talk about?
Focus, motivation, mental stamina, brain fog, mood, neurorecovery: the standard Semax wish list with longer stapled on. Those are marketing themes and forum reports. None has been measured for Adamax in people.
What dose or route details are reported?
Nothing dependable. Scattered vendor and forum reports describe roughly 100 to 300 mcg per day intranasally, usually once daily, extrapolated directly from Semax conventions. There is no studied Adamax regimen, and even cycle length is inconsistent across reports.
How useful is the Semax comparison?
As background only. Semax explains why anyone is interested in this family; it cannot tell you Adamax's dose, duration, effect, or safety. The extra modifications are exactly the reason parent data does not transfer.
Reported practice
Commonly reported protocol
Sparse vendor-analog reports. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail
Evidence
Evidence snapshot
Medsafe identifies Adamax and Semax as ACTH analogues marketed as cognitive enhancers. Public chemical summaries describe Adamax as a synthetic peptide derivative of Semax.
No Adamax-specific human efficacy, pharmacokinetic, or safety trials were found in the cited public databases.
Parent Semax has limited human and animal literature around stroke, optic nerve disease, intranasal brain exposure, neurotrophins, and route-dependent effects. That is relevant background, not direct Adamax evidence.
Medsafe discusses Adamax in a proposal to classify ACTH analogues as prescription medicines. FDA materials separately flag Semax-related compounded peptide risks such as aggregation, impurities, and limited route-specific safety information.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Anecdotal evidence | Verdict |
|---|---|---|---|---|
| Adamax is marketed as a longer-acting Semax. | The cited Adamax human sources do not answer how long it lasts or how it compares with Semax. | The idea is plausible as chemistry logic: terminal modifications can change stability, distribution, and breakdown. Plausible is not the same as demonstrated in people. | Online peptide discussion usually frames Adamax as "Semax, but longer" or a stronger nootropic variant. That is the pitch circulating in the market. | Marketed as longer-acting Semax, but the cited material does not show a measured human duration advantage. |
| Adamax improves focus, motivation, or brain fog. | Direct Adamax human data were not found for focus, motivation, mood, mental stamina, or brain fog. Parent Semax has limited human literature, but not an Adamax cognition trial. | Parent-Semax animal work around neurotrophins, ischemia biology, and route-dependent effects explains why people make the nootropic claim. | Focus, motivation, mental stamina, mood, and brain-fog claims are the main gray-market pitch around Adamax. | Focus and motivation claims show up often in Adamax marketing and forum reports, but they are not measured Adamax effects. |
| Parent Semax evidence carries over to Adamax. | Parent Semax studies involve a different molecule. They explain why Adamax is compared with Semax, but they do not define Adamax's dose, duration, safety, or efficacy. | Semax-family biology is relevant background. The extra Adamax modifications are exactly why direct Adamax evidence matters. | Marketing often collapses Semax, N-Acetyl Semax Amidate, Adamax, and Peptide 021 into one nootropic family. | Parent Semax provides background. It does not tell you Adamax's efficacy, duration, dose, or safety profile. |
| A COA or purity number makes Adamax trustworthy. | Human studies do not identify what is inside a current retail vial or nasal spray. | For Semax-family products, identity, sequence, mass, concentration, sterility, endotoxin, degradation, aggregation, solvent, storage, and route all matter. | Adamax is encountered in the same research-use and gray-market peptide market where product claims can look more precise than they really are. | A purity number is a start, not a full answer on identity or route-specific quality for the route someone intends. |
Bottom line
Main takeaway
Adamax is sold as a longer-lasting Semax. That phrase is the whole product: no published study of Adamax exists, in people or animals.
Keep the family straight: Semax, N-Acetyl Semax Amidate, Peptide 021, and Adamax are different molecules sharing one reputation. A paper on one says nothing measured about the others, and Adamax has no papers.
Everything is missing: pharmacokinetics, route comparison, human outcomes, adverse events, even a peer-reviewed characterization of the molecule. The most solid documents on this page are a Medsafe classification submission and searches that came back empty.
Identity
What it is
Adamax is a Semax-family ACTH-fragment analog with a reported sequence of Ac-MEHFPGPAG-NH2 and terminal modifications associated with Peptide 021. The reported chemistry includes an adamantane group, a bulky hydrophobic attachment meant to improve stability and duration.
Unlike the other Semax variants, Adamax did not come out of a research program. It is a vendor-created molecule with a vendor-defined identity: a name, a reported sequence, a formula on a listing. No published work, human or animal, characterizes it.
The pitch writes itself from there. Semax has a focus and neurorecovery reputation, so a longer Semax sells. A duration claim requires measuring duration, though, and nobody has, so what circulates is Semax folklore with an Adamax label.
How people talk about it online
Adamax talk lives in nootropic gray-market spaces, usually as a comparison: Adamax versus Semax, versus N-Acetyl Semax Amidate, versus Selank. The comparison is the content, since there is no literature to discuss.
Reported goals are the family standard: focus, stamina, motivation, mood, brain fog, with smoother or longer effect as the supposed differentiator. Doses get quoted around 100 to 300 mcg daily, but those are Semax conventions carried over, not Adamax findings.
The most concrete public document naming Adamax is a Medsafe classification submission proposing to capture it, alongside Semax, as a prescription-medicine ACTH analog. Regulators noticed the import traffic before science noticed the molecule.
Use context
Routes, doses, and cycle patterns
Adamax route and dose claims are not pinned down. People discuss it like a Semax upgrade, usually around nasal or research-peptide formats, but available public material does not give one dependable Adamax amount, frequency, or cycle length. Parent-Semax and Semax-family patterns explain the comparison; they are not Adamax dosing guidance.
Human studies and product labels
Parent Semax stroke and rehabilitation studies
- Purpose
- Neurorecovery and BDNF context
- Context
- Parent Semax, not Adamax
- Route
- Intranasal or route-specific clinical context in older Semax literature
- Amount
- Reported in the parent-Semax study only; not an Adamax amount
- Frequency
- Varied by parent-Semax study
- Duration
- Varied by parent-Semax study
This is the published human Semax context people often borrow from. It is not an Adamax regimen.
Parent Semax route-dependence work
- Purpose
- Route biology context
- Context
- Rat intranasal and intraperitoneal Semax study
- Route
- Intranasal and intraperitoneal in rats
- Amount
- Animal-study exposure, not an Adamax human amount
- Frequency
- Varied by parent-Semax study
- Duration
- Varied by parent-Semax study
This supports the idea that route can change Semax-family effects. It is not a human Adamax route guide.
Real-world discussion
Sparse vendor-analog reports
- Purpose
- Cognition discussion
- Context
- Niche nootropic vendors and forums
- Route
- Intranasal spray in most vendor positioning
- Amount
- No consistent community range exists; scattered reports describe roughly 100 to 300 mcg per day, extrapolated from semax
- Frequency
- Once daily in most scattered reports
- Duration
- Inconsistent across reports
Adamax is a vendor-created semax analog with no published literature; community figures are extrapolations, and even the compound's identity is vendor-defined. Not verified as a regimen; context only.
What varies
- Whether the product is actually Adamax rather than parent Semax or N-Acetyl Semax Amidate.
- Whether the route being discussed is nasal, injectable, or just a vague research-use listing.
- Whether the claim is parent-Semax evidence, Adamax anecdote, or vendor claim.
- Whether any COA covers identity, mass, sterility, endotoxin, and lot-specific concentration.
Human data
Human evidence
There is no Adamax human evidence. Public literature and registry searches found no Adamax-specific efficacy, pharmacokinetic, or safety trial, and no published animal study fills the gap. What exists is parent-Semax background, a regulatory classification submission naming Adamax as a marketed cognitive enhancer, and gray-market reports. Duration, dose, benefit, and safety are all unmeasured.
Evidence maturity
Adamax is a vendor-created Semax analog whose claims are borrowed entirely from Semax; no published human study of Adamax itself exists.
Limited human and animal Semax literature supplies the entire rationale for the analog.
An adamantane-group terminal modification is pitched as "longer Semax" on chemistry logic alone.
No indexed PubMed or ClinicalTrials.gov Adamax human trials were found.
Gray-market sprays carry vendor-defined identity, and Medsafe has proposed classifying Adamax with ACTH analogues as prescription medicines.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Adamax-specific human trials | No human trial population found | Public literature and registry review | Adamax | The reviewed sources do not include Adamax-specific human efficacy, pharmacokinetic, or safety trials. | The absence of indexed trials does not prove nobody uses it; it means the reviewed sources cannot answer Adamax-specific duration, dose, benefit, or safety questions. | No direct Adamax human evidence found in the reviewed sources |
| Medsafe ACTH-analogue classification submission | Border/import and regulatory context | Regulatory classification submission | Adamax and Semax named as ACTH analogues marketed as cognitive enhancers | Medsafe recommended ACTH analogues be captured as prescription medicines. | Regulatory source, not an efficacy study. | Strong for market/regulatory context |
| Parent Semax human literature | Stroke rehabilitation and optic nerve disease contexts | Parent-compound studies | Parent Semax, not Adamax | Limited Semax signals in narrow clinical contexts. | Different molecule; Adamax duration, efficacy, and safety still require direct evidence. | Background only |
Use context
Reported use context
The use pattern is easier to see than the dosing evidence. Adamax is discussed as a longer Semax-like option, usually around nasal or research-peptide formats, but the available material does not pin down a dependable Adamax amount, frequency, or cycle length.
Study and label context
Parent Semax appears in stroke, rehabilitation, and optic-nerve literature.
Real-world discussion
Described as longer-acting Semax for focus, motivation, and mental stamina, with scattered reports of roughly 100 to 300 mcg per day intranasal, extrapolated from plain semax. No published literature exists for the analog itself.
Cautions
Safety and unknowns
- No Adamax-specific human safety package was found in the reviewed material.
- The longer-acting claim is not backed by human pharmacokinetic data available here.
- Product identity is a real issue because Adamax sits near Semax, N-Acetyl Semax Amidate, and Peptide 021 in market language.
- Nasal and injectable products carry different quality questions; a vague "research" listing leaves both routes unclear.
- Repeated-use tolerability, drug interactions, psychiatric effects, blood pressure effects, and long-term exposure are outside what parent-Semax mechanism papers can settle.
Product quality
A vial label is only a starting point
Before any benefit claim matters, the product has to actually be Adamax. If the identity is wrong, the rest of the claim falls apart.
A useful Adamax product file would tie the exact lot to identity or mass confirmation, concentration, route-appropriate excipients, route-relevant sterility/endotoxin testing, storage, and degradation data. Semax papers or generic purity numbers do not verify a current Adamax vial or spray.
Exact identity
Adamax, Semax, N-Acetyl Semax Amidate, and Peptide 021 are easy to blur online.
Route-relevant testing
Nasal and injectable products do not have the same quality requirements.
Lot-specific concentration
A label amount does not guarantee the delivered amount.
Degradation and storage
A longer-duration pitch is meaningless if the product is unstable or poorly characterized.
Mechanism
How it is proposed to work
Adamax is sold on a simple idea: take Semax-family CNS interest and modify the molecule so it lasts longer or feels stronger. The chemistry idea is plausible; the human effect still has to be shown directly.
Parent Semax is an ACTH-fragment analogue with animal literature around neurotrophins, ischemia biology, monoamine signaling, and route-dependent effects.
Adamax is described as carrying terminal modifications associated with Peptide 021. Terminal changes can alter stability, charge, distribution, and enzyme breakdown.
The decisive experiment would be direct comparison: Adamax versus Semax in humans, with measured exposure, duration, CNS outcomes, adverse effects, and product identity.
FAQ
Common questions
Is Adamax just longer-acting Semax?
That is the market pitch, not a measured human finding. Adamax is described as a Semax-family designer analogue, but Adamax-specific human pharmacokinetic or duration data were not found.
Can Semax studies be used for Adamax?
They can help explain why people are interested, but they are not Adamax data. Parent Semax, N-Acetyl Semax Amidate, Peptide 021, and Adamax need direct comparisons before the effects can be carried across.
Details
Technical details
Sources
References
- 1.
Other. Classification of Unscheduled Peptides 2025.
Accessed 2026-07-02.
New Zealand Medsafe submission identifying Adamax and Semax as ACTH analogues marketed as cognitive enhancers.
- 2.
Other. Adamax chemical summary 2026.
Accessed 2026-07-02.
Secondary chemical summary used only for public naming, formula, mass, and sequence orientation until an independent chemical registry source is added.
- 3.
PubMed. PubMed search for Adamax peptide evidence 2026.
Accessed 2026-07-02.
Search used to check whether Adamax-specific peer-reviewed human or preclinical records were readily indexed.
- 4.
ClinicalTrials.gov. ClinicalTrials.gov search for Adamax 2026.
Accessed 2026-07-02.
Registry search used to check for Adamax-specific listed human trials.
- 5.
PubMed. The efficacy of Semax in the treatment of patients at different stages of ischemic stroke 2018.
doi:10.17116/jnevro20181183261-68 PMID:29798983 Accessed 2026-06-08.
Human stroke rehabilitation study reporting BDNF, motor-performance, and Barthel-index outcomes; keep regimen details study-reported only.
- 6.
PubMed. Evaluation of therapeutic effect of new Russian drug Semax in optic nerve disease 2000.
PMID:10741256 Accessed 2026-06-08.
Russian-language clinical trial comparing intranasal drops, endonasal electrophoresis, and control groups in optic nerve disease.
- 7.
PubMed. Nootropic and analgesic effects of Semax following different routes of administration 2010.
PMID:21268834 Accessed 2026-06-09.
Rat route-comparison study involving intranasal and intraperitoneal administration; adjacent to, but not evidence for, human subcutaneous use.
- 8.
PubMed. Neurotrophin gene expression in rat brain under the action of Semax, an analogue of ACTH 4-10 2007.
doi:10.1016/j.neulet.2007.02.042 PMID:17353092 Accessed 2026-06-08.
Preclinical intranasal rat study reporting neurotrophin gene-expression effects; mechanism support only.
- 9.
PubMed. Semax, an analog of ACTH(4-7), regulates expression of immune response genes during ischemic brain injury in rats 2017.
doi:10.1007/s00438-017-1297-1 PMID:28255762 Accessed 2026-06-08.
Rat focal-ischemia transcriptome study; useful for mechanism context but not a human route-comparison source.
- 10.
FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee 2026.
Accessed 2026-07-24.
FDA meeting page for the July 23-24, 2026 PCAC review of BPC-157, KPV, TB-500, MOTs-C, emideltide/DSIP, Semax, and Epitalon bulk substances, including the uses evaluated for each, briefing documents, and docket FDA-2025-N-6895.
- 11.
FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks 2026.
Accessed 2026-06-08.
FDA summarizes potential significant safety risks and missing safety information for several nominated peptide bulk substances.